Adam Fein, a pharmaceutical supply chain analyst and longtime 340B critic, predicted that 340B program growth would slow in 2026.

IRA Will Slow 340B Growth in 2026, Predicts Drug Channels’ Adam Fein

December 16, 2025 William Newton, Associate Editor/Senior Writer 340B Report Views

The Inflation Reduction Act (IRA) has created an “inflection point” that will slow 340B program growth in 2026, predicted an [...]

Please Login or Become a Paid Subscriber to View this Content

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!